JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS

J Label Compd Radiopharm 2005; 48: 781-788.

Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jlcr.996

Research Article

Preparation of isotopically labelled benzophenonecontaining lipid analogues

Pingzhen Wang and Thomas A. Spencer*

Department of Chemistry, Dartmouth College, Hanover, NH 03755, USA

Summary

Methods have been developed for isotopic labelling of the benzophenone-containing cholesterol analogue 1 and the fatty acid analogue 2 by use of deuteriated sodium borohydride derivatives. These procedures avoid the commercial catalytic tritiation which had previously been used to obtain ³H-1 and ³H-2. Copyright © 2005 John Wiley & Sons, Ltd.

Key Words: benzophenones; cholesterol; fatty acids; deuteriation; borohydrides

Introduction

We have been preparing benzophenone-containing analogues of sterols¹ and phospholipids² for use as photoaffinity labelling agents in studies of cellular cholesterol efflux and HDL formation.^{3–5} In particular, the cholesterol analogue **1**, known as FCBP,³ and the fatty acid analogue **2** (Figure 1),² were required in radioactive form for use as biochemical research tools. This has been accomplished to date by commercial catalytic tritiation of the brominated *i*-steroid derivative **3**¹ and unsaturated acid **4**², respectively. However, these catalytic tritiations have been somewhat capricious, requiring carefully controlled conditions to avoid undesired reduction of the benzophenone carbonyl group; they are also expensive. Therefore, we wished to developed alternative procedures for isotopic labelling of **1** and **2** that could be conducted in our own laboratories. This paper describes such procedures, employing deuteriated borohydride derivatives.

Results and discussion

The method adopted for labelling of FCBP (1) was an adaptation of that of Malik *et al.*⁶ for tritiation of cholesterol via mild pyridinium chlorochromate

*Correspondence to: T. A. Spencer, Department of Chemistry, Dartmouth College, Hanover, NH 03755, USA. E-mail: taspen@dartmouth.edu

Contract/grant sponsor: USPHS NIH; contract/grant number: HL 67294

Copyright © 2005 John Wiley & Sons, Ltd.

Figure 1. Structures of photoactivable lipid analogues and tritiatable derivatives

(PCC) oxidation to 5-cholesten-3-one followed by reduction with tritiated sodium borohydride (NaB³H₄). In applying this approach to 1, of course, it was necessary initially to protect the benzophenone carbonyl group, which was accomplished by treatment of 1 with acidic ethylene glycol to afford ethylene ketal 5 (Scheme 1). Oxidation of 5 with PCC according to the procedure of Parish et al.⁷ then afforded unconjugated ketone 6. In order to establish the validity of this approach for introduction of isotopic labelling, NaB2H4 was used to reduce 6 back to $3\alpha^{-2}H-5$ (7), which was converted without purification to 3α-²H-1 (8) by hydrolysis in aqueous acidic acetone. The ¹H NMR spectra of 1 and the 8 thus produced are shown in Figure 2, clearly demonstrating essentially complete absence of ${}^{1}H$ at the 3α position of 8. The single absorbance at δ 3.55 in the ²H NMR spectrum of **8** and the essentially complete disappearance of a peak at δ 72.0 in the ¹H-decoupled ¹³C NMR spectrum of 8 confirmed its 3α deuteriation. The appearance of 13 C NMR signals for carbon atoms bonded to ²H depends on experimental conditions such as spin-lattice relaxation time, and can vary from a distinct multiplet to no detectable signal; e.g. see, Cunnane et al.8

As an alternative to commercial catalytic tritiation of unsaturated acid 4 for radiolabelling of 2, we decided to investigate benzylic bromination followed by chemical reduction. This approach was initially explored with the 2:1 mixture of monobromo 9 and dibromo 10 produced by treatment of ester 11² with 1.5 equivalents of NBS in CCl₄ in the presence of benzoyl peroxide (Scheme 2), since we were ultimately interested in radiolabelling phosphatidylcholine analogues containing acid 2 esterified in the C1 or C2 acyl chain.² When the

Scheme 1. (a) HOCH₂CH₂OH, PTSA, PhH, Δ ; (b) PCC, CaCO₃, 4 Å molecular sieves, CH₂Cl₂, rt, 30 min; (c) NaB²H₄, CH₃OH, rt, 1 h; and (d) 9:1 acetone:H₂O, PPTS, Δ

mixture of **9** plus **10** was treated with NaB²H₃CN in HMPA at 90°C for 48 h, according to the procedure of Hutchins *et al.*, ⁹ the ¹H NMR spectrum of the product showed complete disappearance of the peaks at δ 4.98 and 4.54 characteristic of the protons on the brominated positions of **9** and **10**, and the ²H NMR spectrum of the product showed peaks at δ 2.69 and 2.46, indicating clearly the formation of a mixture of **12** and **13**. This conclusion was confirmed by comparison of the ¹³C NMR spectra of **12** plus **13** vs **11**, which showed that the singlets at δ 36.2 and 31.4 in **11**, had, in **12** plus **13**, essentially disappeared and diminished in intensity, respectively.

The reaction of acid **2** itself with NBS under the same conditions likewise produced a ca 2:1 mixture of **14** and **15**. Debromination of **14** plus **15** was initially, but unrewardingly, attempted with zinc in acetic acid. Reduction of **14** plus **15** with NaB²H₃CN, however, again proved successful, resulting in a




Figure 2. ¹H NMR spectra of: (a) FCBP (1) and (b) 3α -²H-1 (8) showing disappearance of peak for 3α -¹H at δ 3.55

Scheme 2. (a) NBS, CCl₄, (PhCO)₂O₂; (b) NaB²H₃CN, HMPA, 90°C, 48 h

moderate yield of a clean mixture of **16** and **17**, which showed changes in its ¹H, ²H, and ¹³C NMR spectra completely analogous to those observed for **12** plus **13**.

Experimental

General methods

¹H NMR and ¹³C NMR spectra were taken at 300 MHz in CDCl₃ unless otherwise indicated. Flash column chromatography was carried out on EM Reagent silica gel 60 (230–400 mesh). Thin layer chromatography (TLC) was performed on polyester sheets precoated with silica gel 60 F-254. All plates were visualized by a UV₂₅₄ light source or staining with 5% phosphomolybdic acid in ethanol. Na₂SO₄ was used as a drying agent unless otherwise noted. Methylene chloride was distilled from CaH₂. Reagents were obtained from Aldrich, and were used without further purification unless otherwise noted.

22-(p-2-Phenyl-[1,3]dioxolan-2-ylphenoxy)-23,24-bisnorcholan-5-en-3β-ol (**5**)

To a solution of 200 mg (0.39 mmol) of **1** and 0.11 ml (1.95 mmol) of ethylene glycol in 5 ml of dry benzene was added 4 mg (0.02 mmol) of *p*-toluenesulphonic acid (PTSA). The mixture was heated at reflux overnight, cooled, diluted with 80 ml of EtOAc, washed with 2×15 ml of saturated NaHCO₃ and 2×10 ml of brine, dried, filtered, and evaporated to give 243 mg of residue which was chromatographed on 8 g of silica gel with 9:1 to 3:1 hexane:EtOAc to give 150 mg (69%) of **5** as a colourless oil: ¹H NMR (300 MHz) δ 7.53 (m, 2H), 7.36 (m, 5H), 6.84 (m, 2H), 5.38 (s, 1H), 4.06 (m, 4H), 3.92 (dd, J = 9.0, 3.0 Hz, 1H), 3.65 (dd, J = 9.0, 7.0 Hz, 1H), 3.55 (m, 1H), 2.27-0.91 (m, 22H), 1.12 (d, J = 6.6 Hz, 3H), 1.04 (s, 3H), 0.74 (s, 3H); ¹³C NMR (75 MHz) δ 159.5, 142.5, 141.1, 134.2, 132.9, 128.4, 128.3, 126.5, 121.8, 114.3, 109.7, 73.2, 71.9, 65.1, 56.7, 53.0, 50.4, 42.8, 42.5, 39.9, 37.6, 36.8, 36.7, 32.2, 32.1, 31.9, 28.1, 24.7, 21.4, 19.7, 17.7, 12.2. Analytically Calculated for C₃₇H₄₈O₄: C, 79.82; H, 8.69. Found: C, 79.60; H, 8.63.

22-(p-2-Phenyl-[1,3]dioxolan-2-ylphenoxy)-23,24-bisnorcholan-5-en- 3β -one (6)

According to a procedure by Parish *et al.*, ⁷ a mixture of 22.7 mg (0.045 mmol) of **5**, 19 mg (0.15 mmol) of CaCO₃ and 4 mg of 4 Å molecular sieves in 4 ml of dry CH₂Cl₂ was stirred at room temperature for 15 min. Then 33 mg (0.15 mmol) of PCC was added. The mixture was stirred at room temperature for 30 min, diluted with 3 ml of brine, and extracted with 3×40 ml of ether. The combined organic layers were passed through a short pad of MgSO₄, and evaporation of the filtrate gave 32 mg of residue which was chromatographed on 3 g of silica gel with 15:1 to 4:1 hexane:EtOAc to give 17 mg (75%) of **6** as a wax-like solid, plus 4.5 mg of overoxidized product: ¹H NMR (500 MHz) δ 7.52 (m, 2H), 7.40 (m, 2H), 7.32 (m, 3H), 6.84 (m, 2H), 5.36 (br, 1H), 4.10 (m, 4H), 3.92 (dd, J = 9.0, 3.0 Hz, 1H), 3.66 (dd, J = 9.0, 7.0 Hz, 1H), 3.30 (dd, J = 16.5, 2.5 Hz, 1H), 2.85 (dd, J = 16.5, 2.5 Hz, 1H), 2.50 (m, 1H), 2.34

(m, 1H), 2.08 (m, 3H), 1.88 (m, 1H), 1.65-0.86 (m, 13H), 1.22 (s, 3H), 1.15 (d, $J = 6.6 \,\mathrm{Hz}$, 3H), 0.77 (s, 3H); $^{13}\mathrm{C}$ NMR (125 MHz) δ 210.6, 159.5, 142.5, 138.8, 134.2, 128.3, 128.2, 127.8, 126.5, 123.1, 114.2, 109.7, 73.2, 65.1, 56.5, 52.9, 49.4, 48.6, 42.8, 39.7, 37.9, 37.1, 36.7, 32.2, 32.0, 29.9, 28.0, 24.6, 21.6, 19.4, 17.7, 12.2.

Conversion of 6 to 8

To a solution of 35 mg (0.063 mmol) of 6 in 2 ml of MeOH was added 8 mg (0.189 mmol) of NaB²H₄. The mixture was stirred at room temperature for 1 h, diluted with 2 ml of brine, extracted with 3 × 30 ml of CH₂Cl₂, washed with 2 × 5 ml of brine, dried over Na₂SO₄, filtered, evaporated to give 36 mg of crude 7. This material was dissolved in 10 ml of 9:1 acetone:H₂O solution and treated with 46 mg (0.185 mmol) of pyridium toluenesulphonate (PPTS). The resulting mixture was heated at reflux overnight, cooled, evaporated, diluted with 50 ml of CH₂Cl₂, and washed with 2 × 5 ml of sat. NaHCO₃ solution and 5 ml of brine. The organic layer was separated and evaporated to give 39 mg of residue which was chromatographed on 3 g of silica gel with 4:1 hexane:EtOAc to give 23 mg (72%) of **8** as a colourless solid: 1 H NMR (500 MHz) δ 7.84-7.76 (m, 4H), 7.57 (m, 1H), 7.49 (m, 2H), 6.95 (m, 2H), 5.38 (br, 1H), 4.01 (dd, $J = 9.0, 3.0 \,\mathrm{Hz}, 1 \,\mathrm{H}$), 3.76 (dd, $J = 9.0, 7.0 \,\mathrm{Hz}, 1 \,\mathrm{H}$), 2.33-0.97 (m, 22H), 1.16 (d, J = 6.5 Hz, 3H), 1.05 (s, 3H), 0.78 (s, 3H); ²H NMR δ 3.55; ¹³C NMR δ 195.8, 163.4, 141.0, 138.5, 132.8, 132.0, 130.0, 129.9, 128.3, 121.8, 114.2, 73.5, 56.6, 52.8, 50.3, 42.8, 42.5, 39.8, 37.5, 36.7, 36.6, 32.1, 32.1, 31.8, 28.0, 24.6, 21.3, 19.6, 17.6, 12.2.

Bromination of methyl 11-[4-(4-methylbenzoyl)-phenyl]-undecanoate (11) to 9 plus 10

To a solution of 316 mg (0.8 mmol) of **11** in 30 ml of CCl₄ was added 216 mg (1.21 mmol) of NBS and 37 mg (0.15 mmol) of benzoyl peroxide. The mixture was heated at reflux for 14 h, cooled, filtered, and evaporated to give 820 mg of residue which was chromatographed on 5 g of silica gel with 25:1 to 20:1 hexane:EtOAc to give 200 mg (53%) of **9** and 109 mg (25%) of **10** as colourless oils. Compound **9**: ¹H NMR δ 7.74 (m, 4H), 7.49 (m, 2H), 7.28 (m, 2H), 4.98 (t, J = 7.5 Hz, 1H), 3.67 (s, 3H), 2.45 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 2.30 (m, 1H), 2.18 (m, 1H), 1.62 (m, 2H), 1.28 (br, 12H); ¹³C NMR δ 196.0, 174.5, 146.6, 143.6, 137.9, 134.9, 130.6, 130.5, 130.0, 127.4, 54.6, 51.7, 40.0, 34.3, 29.5, 29.4, 29.3, 29.1, 28.4, 25.2, 21.9. Compound **10**: ¹H NMR δ 7.79 (m, 4H), 7.51 (m, 4H), 4.98 (t, J = 7.5 Hz, 1H), 4.54 (s, 2H), 3.67 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 2.30 (m, 1H), 2.09 (m, 1H), 1.60 (m, 2H), 1.28 (br, 12H); ¹³C NMR δ 195.5, 174.5, 147.1, 142.5, 137.5, 137.3, 130.8, 130.7, 129.2, 127.6, 54.4, 51.7, 40.0, 34.3, 32.5, 29.5, 29.4, 29.3, 29.1, 28.4, 25.2.

Reduction of 9 plus 10 to 12 plus 13

According to the procedure of Hutchins *et al.*, ⁹ to 34 mg of a 2:1 mixture of **9** and **10** in 1 ml of dry HMPA was added 45 mg (0.72 mmol) of NaB²H₃CN. The mixture was heated at 90°C for 48 h, cooled, and chromatographed directly on 5 g of silica gel with 30:1 to 20:1 hexane:EtOAc to give 11 mg (42%) of a colourless oily mixture of **12** and **13**. ¹H NMR δ 7.73 (m, 4H), 7.28 (m, 4H), 3.68 (s, 3H), 2.69 (t, J = 7.6 Hz, 1H), 2.45 (s, 2.7H), 2.31 (t, J = 7.6 Hz, 2H), 1.65 (m, 4H), 1.30 (s, 12H); ²H NMR δ 2.69, 2.46; ¹³C NMR δ 196.6, 174.6, 148.1, 143.1, 135.6, 135.4, 130.4, 129.1, 128.5, 51.7, 34.3, 31.4, 29.72, 29.70, 29.67, 29.5, 29.49, 29.4, 25.2, 21.9.

Bromination of 11-[4-(4-methylbenzoyl)-phenyl]-undecanoic acid (2) to 14 plus 15

To a solution of 200 mg (0.53 mmol) of **2** in 20 ml of CCl₄ was added 140 mg (0.79 mmol) of NBS and 26 mg (0.11 mmol) of benzoyl peroxide. The mixture was heated at reflux for 18 h, cooled, filtered, and evaporated to give 400 mg of residue which was chromatographed on 5g of silica gel with 4:1 to 2:1 hexane:EtOAc to give 244 mg of light-yellowish oily ca 2:1 mixture of **14** and **15**. Rechromatography on 15g of silica gel effected separation to give pure **14** and **15**: Compound **14**: 1 H NMR δ 7.76 (m, 4H), 7.49 (m, 2H), 7.28 (m, 2H), 4.98 (t, J = 7.5 Hz, 1H), 2.45 (s, 3H), 2.33 (t, J = 7.5 Hz, 2H), 2.29 (m, 1H), 2.18 (m, 1H), 1.63 (m, 2H), 1.28 (br, 12H); 13 C NMR δ 196.0, 180.1, 146.6, 143.7, 137.9, 134.9, 130.6, 130.5, 130.0, 127.4, 54.6, 40.0, 34.2, 29.5, 29.48, 29.4, 29.2, 29.1, 28.4, 24.9, 21.9. Compound **15**: 1 H NMR δ 7.78 (m, 4H), 7.51 (m, 4H), 4.98 (t, J = 7.5 Hz, 1H), 4.55 (s, 2H), 2.30 (t, J = 7.5 Hz, 2H), 2.26 (m, 1H), 2.17 (m, 1H), 1.63 (m, 2H), 1.29 (br, 12H); 13 C NMR δ 195.5, 179.8, 147.1, 142.5, 137.5, 137.3, 130.8, 130.7, 129.2, 127.6, 54.4, 40.0, 34.2, 32.5, 29.5, 29.4, 29.3, 29.2, 29.1, 28.4, 25.2.

Reconversion of 14 and 15 to 16 and 17

To a mixture of 42 mg of **14** and **15** in 0.8 ml of dry HMPA was added 70 mg (1.06 mmol) of NaB²H₃CN. The mixture was heated at 80°C for 48 h, cooled, and chromatographed directly on 3 g of silica gel with 4:1 to 3:1 hexane:EtOAc to give 15 mg (45%) of a colourless oily mixture of **15** and **16**. ¹H NMR δ 7.74 (m, 4H), 7.28 (m, 4H), 2.69 (m, 1H), 2.45 (br, 2.7H), 2.37 (t, J = 7.2 Hz, 2H), 1.65 (m, 4H), 1.32 (s, 12H); ¹H NMR δ 2.69, 2.45; ¹³C NMR δ 196.6, 179.1, 148.1, 143.2, 135.6, 135.4, 130.5, 130.5, 129.1, 128.5, 34.1, 31.4, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 24.9, 21.9.

Conclusion

Convenient, reliable procedures for isotopic labelling of photoactivable cholesterol analogue 1 and fatty acid analogue 2 have been developed, using

NaB²H₄ and NaB²H₃CN, respectively, that will be useful as less expensive alternatives to commercial catalytic tritiation for introduction of radiolabels into these biochemical research tools.

Acknowledgements

This research was supported by USPHS NIH grant HL 67294.

References

- Spencer TA, Wang P, Li D, Russel JS, Blank DH, Fielding PE, Fielding CJ. J Lipid Res 2004; 45: 1510–1518.
- 2. Wang P, Blank DH, Spencer TA. J Org Chem 2004; 69: 2693-2702.
- 3. Fielding PE, Russel JS, Spencer TA, Hakamata H, Nagao K, Fielding CJ. *Biochemistry* 2002; **41**: 4929–4937.
- 4. Fielding PE, Chau P, Liu D, Spencer TA, Fielding CJ. *Biochemistry* 2004; **43**: 2578–2586.
- 5. Nakamura Y, Kotite L, Gan Y, Spencer TA, Fielding CJ, Fielding PE. *Biochemistry* 2004; **43**: 14811–14820.
- 6. Malik S, Kenny M, Ahmad S. J Label Compd Radiopharm 1992; 31: 861-863.
- 7. Parish EJ, Luo C, Parish S, Heiderpriem RW. Synth Commun 1992; 22: 2839–2847.
- 8. Cunnane SC, Descomps B, Williams SCR, Haycock PR, Chen Z-Y, Mendy F. *Chem Phys Lipids* 1992; **63**: 259–263.
- 9. Hutchins RO, Kandasamy D, Maryanoff CA, Masilamani D, Maryanoff BE. *J Org Chem* 1977; **42**: 82–91.
- 10. De Lucca GV, Liang J, De Lucca I. J Med Chem 1999; 42: 135–152.